supernus biogen - Search News

Order byBest matchMost fresh

News

SAGE, postpartum depression and Supernus

Zacks Investment Research on M… · 7h

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Sage Therapeutics SAGE announced that Supernus Pharmaceuticals SUPN has agreed to acquire SAGE through a tender offer of $8.50 per share in cash, totaling around $561 million. Additionally, shareholders will receive a non-tradable contingent value right (CVR) worth up to $3.

Continue reading

· 1d · on MSN

Supernus enters depression drug market with up to $795 million Sage deal

Fierce Pharma · 1d

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

After rebuffing Biogen, Sage pairs off with Supernus

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

GlobalData on MSN1d

Supernus makes depression drug play with $795m Sage buyout

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

1d

Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results